Advanced Search

 

Study ID Status Title Patient Level Data
116706 Active, Not Recruiting Pooled analysis of the assessment of the association of lung function improvements on COPD related exacerbations and other endpoints
116715 Completed A single-center, randomized, blinded, placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in single and repeat doses, with and without food, in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
116741 Completed A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers after Single and Repeat Dosing Study Listed on ClinicalStudyDataRequest.com
116747 Completed PGx6202: Genetic Evaluation of Efficacy and Safety Endpoints in Patients with Ovarian Cancer in VEG110655/VEG114012
116753 Completed A randomized, double-blind, placebo-controlled, crossover study to evaluate the influence of the A118G polymorphism in the mu opioid receptor gene (OPRM1) on effects of GSK1521498 and naltrexone on physiological and behavioural markers of brain function in healthy social drinkers Study Listed on ClinicalStudyDataRequest.com
116760 Completed Safety and immunogenicity study of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine GSK1437173A when administered subcutaneously versus intramuscularly in adults aged 50 years or older Study Listed on ClinicalStudyDataRequest.com
116771 Completed European Survey of Patient and Prescriber Understanding of Risks Associated with Trobalt™
116796 Completed Immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults with a prior episode of herpes zoster Study Listed on ClinicalStudyDataRequest.com
116797 Completed An open-label, randomized, single dose, three-way crossover study to determine the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine (5mg) and losartan (100mg) in healthy adult male and female Subjects under fasting conditions Study Listed on ClinicalStudyDataRequest.com
116798 Completed An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects under Fasting Conditions Study Listed on ClinicalStudyDataRequest.com
116799 Completed An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions Study Listed on ClinicalStudyDataRequest.com
116806 Terminated An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state Study Listed on ClinicalStudyDataRequest.com
116829 Completed Clinical and cost impact of complete and incomplete rotavirus vaccination
116844 Completed Meta-Analysis Results Report for DB2116844: Meta-analysis of DB2113360 and DB2113374: an Integrated Review of Transition Dyspnoea Index data for Umeclidinium/Vilanterol, Umeclidinium, Vilanterol and Tiotropium over 24 Weeks in Subjects with COPD
116853 Completed A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (with an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning via a Dry Powder Inhaler with Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily via a Reservoir Inhaler in Subjects with Chronic Obstructive Pulmonary Disease Study Listed on ClinicalStudyDataRequest.com
116863 Completed A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Study Listed on ClinicalStudyDataRequest.com
116878 Terminated Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
116891 Completed A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers Study Listed on ClinicalStudyDataRequest.com
116926 Completed Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) when administered in children Study Listed on ClinicalStudyDataRequest.com
116947 Completed Pazopanib Sarcoma Cost Effectiveness Model
116952 Completed WEUSKOP6416: Evaluating serious pneumonia in subjects with Chronic Obstructive Pulmonary Disease (COPD) to inform risk minimization: A Retrospective Observational Study
116960 Completed DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a fixed combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects with COPD Who Continue To Have Symptoms on Tiotropium Study Listed on ClinicalStudyDataRequest.com
116961 Completed Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD Study Listed on ClinicalStudyDataRequest.com
116974 Completed A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116975 Completed Population Meta-Pharmacokinetic Analysis of umeclidinium bromide/vilanterol from two Phase III studies (DB2113361, DB2113373) in Adults with Chronic Pulmonary Obstructive Disease (COPD)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.